The moves come as Bayer seeks approval from Berkeley leaders for a new 30-year master plan that would allow the Germany-based company to build 1 million square feet of production, research and office space and add some 1,000 employees over that period.
At the forefront of Bayer's big plans are cell therapies, which employ genetically engineered cells to fix blood cancers and potentially more diseases, and one-shot-and-done gene therapies that insert a correct copy of a gene to replace a defective, disease-causing gene.
Reproductive rights have been a flashpoint in national politics for decades, with the stakes surging after the Supreme Court shredded the right to an abortion. In the current presidential campaign, the battle over abortion has swelled and morphed to encompass in vitro fertilization (IVF), which has now moved rapidly from widely accepted to partisan hot button.
This dramatic shift was highlighted by the February decision of the Alabama Supreme Court that granted personhood rights to frozen IVF embryos, signaling that...
It was 2020. I was wrapping up grade nine science with a solid 60 per cent, hoping that if anyone saw my failed tests in the recycling bin, it would contribute to an air of mystery about me. This reason...
IT’S A COMMON STORY, banal, even: a child of privilege, an heir apparent, leaves for college to get a good enough education—and maybe have a little fun—before taking over the family business. But the child, away from the nest for...
When a person with a uterus decides to freeze their eggs, any number of things can go wrong. Ice crystal can form, killing an otherwise viable ovum. A fertilized egg may fail to properly implant, or the egg may...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.
